Skip to content
Screener

Savara SVRA Cash & Equivalents

Cash & Equivalents at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$121.75M+105%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$570.39M+43.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$145.32M+205%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$96.72M+35.6%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$360.25M+65.4%
PVL
Palvella TherapeuticsPVLA
$206.39M+173%

Other financials

Income statement

See full
Revenue-—
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+151%
Enterprise value$1.18B+142%

Profitability

See full
Operating margin-19,183.3%—
Net margin-19,305.1%—
FCF margin-15,518.7%—

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Savara’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219371
Line itemMarch 31, 2026December 31, 2025
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$38,791$33,180
Short-term investments163,981202,522
Prepaid expenses and other current assets6,4935,914
Total current assets209,265241,616
Property and equipment, net130100

Cover / Front Matter

FAQ

What is Savara's cash & equivalents?
Savara (SVRA) reported cash & equivalents of $38.79M in Q1 2026.
How has Savara's cash & equivalents changed year-over-year?
Savara's cash & equivalents increased by 98.4% year-over-year, from $19.56M to $38.79M.
What is the long-term trend for Savara's cash & equivalents?
Over 5 years (2020 to 2025), Savara's cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $22.88M to $33.18M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Savara's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude